Downregulation of miR-195 promotes prostate cancer progression by targeting HMGA1

Zhang, Xiaowen; Tao, Tao; Liu, Chunhui; Guan, Han; Huang, Yeqing; Xu, Bin; Chen, Ming

doi:10.3892/or.2016.4797

Cited by 45 publications

(31 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In striking contrast, endometrial cancer tissue samples showed a significant decrease in fourteen tumor-suppressive miRNAs (Figure 1C). It is of interest to note here that all of the fourteen downregulated miRNAs, namely, miR-26a-5p [22, 23], miR-150-5p [24, 25], let-7f-5p [26, 27], miR-26b-5p [22, 23, 28], let-7c-5p [26, 27], miR-23b-5p [29-31], miR-126-3p [32], miR-125b-5p [33], hsa-miR-195-5p [34, 35], miR-424-5p [36, 37], hsa-miR-374a-5p [38-40], let-7a-5p [26, 27] , let-7e-5p [26, 27], and miR-125a-5p [41, 42] are known to have tumor-suppressive function in many cancers. Taken together with the upregulated genes, our results identify a panel of miRNAs that correlates with the tumor phenotype.…”

Section: Resultsmentioning

confidence: 99%

Identification of novel diagnostic and prognostic miRNA signatures in endometrial cancer

et al. 2017

View full text Add to dashboard Cite

With the goal of identifying diagnostic and prognostic biomarkers in endometrial cancer, miRNA-profiling was carried out with formalin-fixed paraffin embedded (FFPE) tissue samples from 49 endometrial cancer patients. Results using an 84-cancer specific miRNA panel identified the upregulation of miR-141-3p and miR-96-5p along with a downregulation of miR-26, miR-126-3p, miR-23b, miR-195-5p, miR-374a and let-7 family of miRNAs in endometrial cancer. We validated the dysregulated expression of the identified miRNAs in a panel of endometrial cancer cell-lines. Immunohistochemical analysis of the tissue micro array derived from these patients established the functional correlation between the decreased expression of tumor suppressive miRNAs and their target oncogenes: ERBB2, EGFR, EPHA2, BAX, GNA12, GNA13, and JUN. Comparative analysis of the samples from the patients with extended progression-free survival (PFS) ( > 21 months) versus the patients with the PFS of < 21 months indicated increased expression of tumor suppressive miR-142-3p, miR-142-5p, and miR-15a-5p in samples from extended PFS patients. In addition to defining a specific set of miRNAs and their target genes as potential diagnostic biomarkers, our studies have identified tumor suppressive miR-142 cluster and miR-15a as predictors of favorable prognosis for therapy response in endometrial cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Identification of novel diagnostic and prognostic miRNA signatures in endometrial cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…HMGA1 is primarily expressed in fetal tissues (Hynes et al, 1994) and many cancer tissues, such as colorectal cancer (Williama et al, ), breast cancer (Cianfrocca et al, ), pancreatic cancer (Piscuoglio et al, ), ovarian cancer (Liu et al, ), and prostate cancer (Zhang et al, ). In this study, we found that HMGA1 expression in breast cancer tissues was stronger than that in normal breast tissues, which is consistent with the previous reports on breast cancer cell lines and breast cancer tissues (Liu et al, ; Sepe et al, ).…”

Section: Discussionmentioning

confidence: 99%

“…High mobility group A1 (HMGA1), a member of the HMGA family, is highly expressed during embryogenesis (Pegoraro et al, ), while HMGA1 protein expression levels are low or undetectable in normal adult tissues (Zhou et al, ; van't Veer et al, ). Studies have shown that HMGA1 plays an important role in several types of cancers, such as breast cancer (Cianfrocca et al, ), colorectal cancer (Williama et al, ), pancreatic cancer (Piscuoglio et al, ), prostate cancer (Zhang et al, ), ovarian cancer (Liu et al, ), and lung cancer (Lin et al, ). Furthermore, some studies have reported that HMGA1 is highly expressed in human breast cancer tissues, and the overexpression of HMGA1 is associated with breast cancer progression (Huang et al, ).…”

mentioning

confidence: 99%

HMGA1 Overexpression is Associated With the Malignant Status and Progression of Breast Cancer

Cao

et al. 2018

The Anatomical Record

View full text Add to dashboard Cite

Breast cancer is the most common malignant tumor among women, and the incidence and mortality of breast cancer has rapidly increased in recent years. Studies have indicated that high mobility group A1 (HMGA1), an important member of the HMGA family, plays a role in the pathogenesis and progression of malignant tumors, including breast cancer. This study aims to evaluate the effect of HMGA1 in breast cancer. Interestingly, we found that HMGA1 expression was significantly higher in breast cancer tissues than in adenoma tissues and closely correlated with the clinical stage and histological grade in breast cancer patients. Further study showed that HMGA1 knockdown inhibited the proliferation and migration of breast cancer cells. Thus, the results demonstrated that HMGA1 could act as an independent prognostic indicator in breast cancer. HMGA1 expression was closely correlated with the clinical stage, histological grade, and tumor size in breast cancer patients and breast cancer progression in transgenic MMTV-PyMT mice. Anat Rec, 301:1061-1067, 2018. © 2018 Wiley Periodicals, Inc.

show abstract

“…miR-195 inhibited the tumor angiogenesis and growth by suppressing IRS1 in breast cancer [17]. In prostate cancer cells, miR-195 functions as a tumor suppressor gene by suppressing HMGA1 [30]. In esophageal squamous cell carcinoma cells, Fu et al manifested that miR-195 downregulation inhibited cell proliferation and invasion by targeting Cdc42 [16].…”

Section: Discussionmentioning

confidence: 99%

miR-195 Regulates Proliferation and Apoptosis through Inhibiting the mTOR/p70s6k Signaling Pathway by Targeting HMGA2 in Esophageal Carcinoma Cells

Wang

et al. 2017

Disease Markers

View full text Add to dashboard Cite

miR-195 is related to tumorigenesis and frequently inhibits cell proliferation and promotes apoptosis in various cancers, including esophageal carcinoma (EC). The mTOR/p70s6k signaling pathway, which is the major target pathway for HMGA2, regulates the survival and cell proliferation of many tumors and is commonly active in EC. The relationships of miR-195, HMGA2, and the mTOR/p70s6k signaling pathway in EC, however, remain unknown. In the present study, we found that the miR-195 level was significantly downregulated in EC tissues, while the mRNA expressions of HMGA2 were significantly upregulated. Dual-luciferase reporter assay demonstrated that HMGA2 is a target of miR-195. MTT assay and flow cytometry revealed that miR-195 overexpression inhibited cell proliferation and induced apoptosis by targeting HMGA2. We also found that HMGA2 restored the inhibitory effect of miR-195 on phosphorylation of mTOR and p70S6K. Furthermore, rapamycin, a specific inhibitor of the mTOR/p70S6K signaling pathway, decreased the levels of Ki-67 and Bcl-2/Bax ratio, inhibited cell proliferation, and promoted apoptosis in EC cells. In conclusion, upregulation of miR-195 significantly suppressed cell growth and induced apoptosis of EC cells via suppressing the mTOR/p70s6k signaling pathway by targeting HMGA2.

show abstract

Downregulation of miR-195 promotes prostate cancer progression by targeting HMGA1

Cited by 45 publications

References 29 publications

Identification of novel diagnostic and prognostic miRNA signatures in endometrial cancer

Identification of novel diagnostic and prognostic miRNA signatures in endometrial cancer

HMGA1 Overexpression is Associated With the Malignant Status and Progression of Breast Cancer

miR-195 Regulates Proliferation and Apoptosis through Inhibiting the mTOR/p70s6k Signaling Pathway by Targeting HMGA2 in Esophageal Carcinoma Cells

Contact Info

Product

Resources

About